The viral safety of intravenous immune globulin

Clinical and Experimental Immunology, Supplement

Volumn 104, Issue SUPPL. 1, 1996, Pages 35-42

  Yap, P L ^a,b  

^a Edinburgh and SE Scotland Blood Transfusion Service ^*  (United Kingdom)

^b Blood Transfusion Service   (United Kingdom)

Author keywords

HCV; Immunoglobulin; IVIG

Indexed keywords

IMMUNOGLOBULIN;

CONFERENCE PAPER; DRUG SAFETY; HEPATITIS C; HUMAN; PRIORITY JOURNAL; SEROCONVERSION; VIRUS INACTIVATION; VIRUS TRANSMISSION;

HEPATITIS C; HIV INFECTIONS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS;

EID: 0029877802     PISSN: 09642536     EISSN: None     Source Type: Journal    
DOI: 10.1111/cei.1996.104.s1.35     Document Type: Article

References (69)

1. Yap PL (ed). Clinical Applications of Intravenous Immunoglobulin Therapy. London: Churchill Livingstone, 1992.
2. Lane RS. Non-A, non-B hepatitis from intravenous immunoglobulin. Lancet 1983; ii:974-5.
3. Lever AML, Webster ADB, Brown D, Thomas HC. Non-A, non-B hepatitis occuring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet 1984; ii:1062-4.
4. Ochs HD, Fischer SH, Virant FS et al. Non-A, non-B hepatitis and intravenous immunoglobulin. Lancet 1985; i: 404-5.
5. Ochs HD, Fischer SF, Virant FS et al. Non-A, non-B hepatitis after intravenous immunoglobulin. Lancet 1986; i:323.
6. Weiland O, Mattson L, Glaumann H. Non-A, non-B hepatitis after intravenous gammaglobulin. Lancet 1986; i: 976-7.
7. Hammarström L, Smith CIE. IgM production in hypogammaglobulinaemia patients during non A, non B hepatitis. Lancet 1986; i:743.
8. Bjorkander J, Cunningham-Rundles C, Lundin P et al. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinaemia or IgG subclass deficiency. Am J Med 1988; 84:107-11.
9. Williams PE, Yap PL, Gillon J et al. Transmission of non-A, non-B hepatitis by pH4 treated intravenous immunoglobulin. Vox Sang 1989; 57: 15-18.
10. Suomela H. Inactivation of viruses in blood and plasma products. Transf Med Rev 1993; 7:42-57.
11. Bjoro K, Froland SS, Yan Z et al. Hepatitis C infection in patients with primary hypogammaglobulinaemia after treatment with contaminated immune globulin. N Engl J Med 1994; 331:1607-11.
12. Choo QI, Kuo G, Weiner AJ et al. Isolation of a cDNA clone derived from a blood borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
13. Yap PL, McOmish F, Webster ADB et al. Hepatitis C virus transmission by intravenous immunoglobulin. J Hepatol 1994; 21:455-60.
14. Murray R, Ratner F. Safety of immune serum globulin with respect to homologous serum hepatitis. Proc Soc Exp Biol Med 1953; 83:554-5.
15. Barandun S, Kistler P, Jennet F, Isliker H. Intravenous administration of human gammaglobulin. Vox Sang 1962; 7: 157-74.
16. Iwarson S, Wejstal R, Ruttimann E. Non-A, non-B hepatitis associated with the administration of intravenous immunoglobulin-transmission studies in chimpanzees. Serodiagn Immunother 1987; 1: 261-6.
17. Leen CLS, Yap PL, Neill G et al. Serum ALT levels in patients with primary hypogammaglobulinaemia receiving replacement therapy with intravenous immunoglobulin or fresh frozen plasma. Vox Sang 1986; 50:26-32.
18. Rousell RH, Good RA, Pirofsky B, Schiff RI. Non-A, non-B hepatitis and the safety of intravenous immune globulin, pH 4.2: a retrospective survey: preliminary communication. Vox Sang 1988; 54:6-13.
19. Gutteridge CN, Veys P, Newland AC. Safety of intravenous immunoglobulin for treatment of autoimmune thrombocytopenia. Acta Haematol 1988; 79:88-90.
20. Yap PL. Supply of blood products. Br Med J 1991; 302: 1538.
21. Foster PF, McIntosh RV. Current safety of clotting factor concentrates. Arch Pathol Lab Med 1990; 114:1188-9 (Letter).
22. Lockner D, Bratt G, Lindborg A, Tornebohm E. Acute unidentified hepatitis in a hypogammaglobulinaemic patient on intravenous gammaglobulin successfully treated with interferon - case report. Acta Med Scand 1987; 221:413-15.
23. Garson JA, Tuke PW, Makris M et al. Demonstration of viraemia patterns in haemophiliacs treated with hepatitis-C-virus-contaminated factor VIII concentrates. Lancet 1990; 336:1022-5.
24. Simmonds P, Zhang LQ, Watson HG et al. Hepatitis C quantification and sequencing in blood products, haemophiliacs, and drug users. Lancet 1990; 336:1469-72.
25. Garson JA, Preston FE, Makris M et al. Detection by PCR of hepatitis C virus in factor VIII concentrates. Lancet 1990; 335:1473 (Letter).
26. Hoppe HH, Mester T, Henning W, Krebs HJ. Prevention of Rh-immunisation. Modified production of IgG anti-Rh for intravenous application by ion-exchange chromatography (IEC). Vox Sang 1973: 25:308-16.
27. Renger FG, Frank KH, Reimann W et al. Erste Ergebnisse zur Virushepatitis C als Klinisch and immunologisch definierbare Form der non-A, non-B-Hepatitiden. Med Aktuell 1979; 11:518-19.
28. Dittmann S, Roggendorf M, Durkop J et al. Long term persistence of hepatitis C virus antibodies in a single source outbreak. J Hepatol 1991; 13:323-7.
29. Power JP, Lawlor E, Davidson F et al. Hepatitis C viraemia in recipients of Irish intravenous anti-D immunoglobulin. Lancet 1994; 334:116-17.
30. Power JP, Lawlor E, Davidson F et al. Molecular epidemiology of an outbreak of infection with hepatitis C virus in recipients of anti-D immunoglobulin. Lancet 1995; 345:1211-13.
31. Lee ML, Courter SG, Tait D, Kingdon HS. Long term evaluation of intravenous immune globulin preparation with regard to non-A, non-B hepatitis safety. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. New York: Alan R. Liss, 1988:596-9.
32. Finlayson JS, Tankersley DL. Anti-HCV screening and plasma fractionation: the case against. Lancet 1990; 335: 1274-5.
33. Outbreak of hepatitis C associated with intravenous immunoglobulin administration - United States, October 1993-June 1994. Morbidity & Mortality Weekly Report 1994; 43:505-9.
34. Pawlotsky J-M, Bouvier M, Deforges L et al. Chronic hepatitis C after high dose intravenous immunoglobulin. Transfusion 1994; 34:86-7.
35. Yu MW, Mason BL, Guo ZP et al. Hepatitis C transmission associated with intravenous immunoglobulins. Lancet 1995; 345:1173-4.
36. Nubling CM, Willkommen H, Löwer J. Hepatitis C transmission associated with intravenous immunoglobulins. Lancet 1995; 345:1174.
37. Keusch GT, Olsson RA, Troncale FJ. Asymptomatic hepatitis in adults given gamma-globulin for prophylaxis. Arch Int Med 1969; 124:326-9.
38. Petrilli FL, Crovari P, de Flora S. Hepatitis B in subjects treated with a drug containing immunoglobulins. J Infect Dis 1977; 135:252-8.
39. John TJ, Ninan GT, Rajagopalan MS et al. Epidemic hepatitis B caused by commercial human immunoglobulin. Lancet 1979; i:1074.
40. Tabor E, Gerety R. Transmission of hepatitis B by immune serum globulin. Lancet 1979; ii:1293.
41. de Silva LC, Sette H, Antonacio F, Lopes JD. Commercial gammaglobulin (CGG) as a possible vehicle of transmission of HBsAg in familial clustering. Rev Inst Med Trop Sao Paulo 1977; 19:352-4.
42. Nakamura S, Sato T. Acute hepatitis B after administration of gammaglobulin. Lancet 1976; i:487.
43. Dioguardi N, de Franchis R. Hepatitis B surface antigen in commercial gammaglobulin. Lancet 1975; ii:816.
44. Berg R, Bjorling H, Berntsen K, Espmark A. Recovery of Australia antigen from human plasma products separated by a modified Cohn fractionation. Vox Sang 1972: 22:1-13.
45. Leveque P, Dronet J, Schmitt Lauesler R et al. HBs antigen in human plasma fractions. Vox Sang 1975; 28:1-8.
46. Webster ADB, Lever AML. Non-A, non-B hepatitis after intravenous immunoglobulin. Lancet 1986; i:322.
47. Centers for Disease Control. Safety of therapeutic immunoglobulin preparations with respect to transmission of human T-lymphocyte virus type I/lymphadenopathy associated virus infection. Morbidity and Mortality Weekly Report 1986; 35:231-2.
48. Mitra G, Wong MF, Mozen MM et al. Elimination of infectious retroviruses during preparation of immunoglobulin. Transfusion 1986; 36:394-7.
49. Wells MA, Wittek AE, Epstein JS et al. Inactivation and partition of human T-cell lymphotrophic virus, type III, during ethanol fractionation of plasma. Transfusion 1986; 26:210-13.
50. Kempf C, Jentsch P, Barre-Sinoussi FB et al. Inactivation of human immunodeficiency virus (HIV) by low pH and pepsin. J Acquir Immune Defic Syndr 1991; 4:828-30.
51. Simons JN, Pilot-Matias TJ, Leary TP et al. Identification of two flavivirus-like genomes in the GB hepatitis agent. Proc Natl Acad Sci USA 1995; 92:3401-5.
52. Pennell RB. The distribution of certain viruses in the fractionation of plasma. In: Hartmann FW, Lo Grippo GA, Mateer JG, Barron J, eds. Hepatitis Frontiers. London: Churchill J&A, 1957:297-310.
53. Horst H-A, Schmitz N, Glinike C et al. Seroconversion for hepatitis C virus antibody in bone marrow recipients treated with immune globulin. N Engl J Med 1991; 325:132-3.
54. Ward KN, Morgan G, Ashworth K et al. Spurious outbreak of HCV in bone-marrow recipients treated with cytomegalovirus immunoglobulin. Lancet 1992; 340:1290-1.
55. Dodd LG, McBride JH, Gitnick GL et al. Prevalence of non-A, non-B hepatitis/hepatitis C virus antibody in human immunoglobulins. Am J Clin Pathol 1992; 97:108-13.
56. Quinti I, Sacco G, el Salman D et al. Infection with hepatitis C virus. Intravenous immunoglobulin may still infect patients. Brit Med J 1994; 308:856 (Letter).
57. Taliani G, Guerra E, Rosso R et al. Hepatitis C virus infection in hypogammaglobulinaemic patients receiving long-term replacement therapy with intravenous immunoglobulin. Transfusion 1995; 35:103-7.
58. Schiano TD, Bellary SV, Black M. Possible transmission of hepatitis C virus infection with intravenous immunoglobulin (Letter). Ann Int Med 1995; 122:802-3.
59. Quinti I, Paganelli R, Scala E et al. Hepatitis C virus antibodies in gammaglobulin. Lancet 1990; 336:1337.
60. Lafrere JJ, Mariotti M, Trepo C et al. Testing for HCV-RNA in commercial intravenous immunoglobulins. Lancet 1993; 341:834-5.
61. Yu MYW, Mason BL, Tankersley DL. Detection and characterization of hepatitis C virus RNA in immune globulins. Transfusion 1994; 34:596-602.
62. Yei S, Yu MW, Tankersley DL. Partitioning of hepatitis C virus during Cohn Oncley fractionation of plasma. Transfusion 1992; 32:824-8.
63. Vrielink H, van der Poel CL, Reesink HW et al. Transmission of hepatitis C virus by anti-HCV-negative blood transfusion. Vox Sang 1995; 68:55-6.
64. Reid KG, Cuthbertson B, Jones ADL, McIntosh RV. Potential contribution of mild treatment at pH4 to the viral safety of human immunoglobulin products. Vox Sang 1988; 55:75-80.
65. Louie RE, Galloway CJ, Dumas ML et al. Inactivation of Hepatitis C virus in low pH intravenous immunoglobulin. Biologicals 1994; 22:13-9.
66. Nowak T, Gregerson JP, Klockmann U et al. Virus safety of human immunoglobulins: efficient inactivation of hepatitis C and other human pathogenic viruses by the manufacturing procedure. J Med Virol 1992; 36:209-16.
67. Ebeling F, Baer M, Hormila P et al. Tolerability and kinetics of a solvent-detergent-treated intravenous immunoglobulin preparation in hypogammaglobulinaemia patients. Vox Sang 1995; 69:91-94.
68. Dodd RY. Viral contamination of blood components and approaches for reduction of infectivity. Immunol Invest 1995; 24:25-48.
69. Cuthbertson B, Perry RJ, Foster PR et al. Factors influencing the viral safety of intravenous immunoglobulin. J Infect 1987; 15:125-33.